The Effects of Thoracic Epidural Analgesia during Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma
Table 1
Patient characteristics.
Characteristics
Group C ()
Group E ()
value
Sex (M/F)
128/46
37/12
Age (years)
62.8 ± 9.8
65.4 ± 10.3
0.111
Height (cm)
163.5 ± 8.6
162.9 ± 7.7
0.666
Weight (kg)
64.1 ± 12.7
65.3 ± 12.9
0.587
Underlying disease
Hypertension (%)
45 (25.9)
16 (32.7)
0.367
Diabetes mellitus (%)
49 (28.2)
8 (16.3)
0.099
Cardiovascular disease (%)
5 (2.9)
3 (6.1)
0.280
Respiratory disease (%)
2 (1.1)
1 (2.0)
0.632
Chronic kidney disease (%)
7 (4.0)
2 (4.1)
0.985
Tumor count
0.229
Less than 1 (1≤)
142 (81.6)
36 (73.5)
2 or more (≥2)
32 (18.4)
13 (26.5)
Tumor size
0.278
<2 cm
138 (79.3)
43 (87.8)
2-3 cm
34 (19.5)
6 (12.2)
3–5 cm
2 (1.1)
0 (0.0)
Procedure time (min)
47.8 ± 18.0
41.4 ± 16.1
0.025
AST (before RFA) (IU/L)
51.4 ± 38.8
43.1 ± 27.5
0.161
ALT (before RFA) (IU/L)
39.5 ± 33.6
39.7 ± 41.2
0.972
AST (after RFA) (IU/L)
50.7 ± 34.8
43.8 ± 30.6
0.211
ALT (after RFA) (IU/L)
39.2 ± 29.7
36.4 ± 29.6
0.566
Child–Pugh class (A/B)
161/13
49/0
MELD score
5.9 ± 3.9
4.6 ± 3.2
0.127
Length of hospital stay (day)
1.3 ± 0.9
1.4 ± 1.3
0.387
All measured values are presented as mean ± standard deviation or number of patients (%). AST = aspartate aminotransferase; ALT = alanine aminotransferase; MELD = Model for End-Stage Liver Disease. compared with Group C.
